F Fuzkk Atlas of Asia, the Middle East, Canada, Australia and Africa
#88FUZKK atlas leaders 1–100

Mesoblast

Australia · Australia and New Zealand

BiologicsCell and gene therapy

Manufacturing profile

Biologics
Cell and gene therapy

Country: Australia

Macro-region: Australia and New Zealand

Selection basis

The company is placed in positions 1–100 as a major manufacturer, biopharmaceutical group, generics/API/CDMO leader or a significant regional manufacturing participant.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

  1. 1Cell bank or microbial seed
  2. 2Upstream culture or fermentation
  3. 3Clarification and chromatography
  4. 4UF/DF, formulation and sterile filtration
  5. 5SEC, CE, LC-MS, ELISA, qPCR and bioassay QC
  6. 6Starting-material and cell-bank control
  7. 7Cell expansion or vector production
  8. 8Purification, concentration and formulation
  9. 9Identity, viability, potency and qPCR

Relevant FUZKK packages

Global API & Biosimilars QC SuiteLabEx QC SuiteCell & Gene Therapy / Viral Vector QC Suite

Product/API utilities

Residual Host Cell DNA Quality CheckerResidual Host Protein CheckerVector Genome Titer q PCR AnalyzerReplication Competent Virus RCV Quality Checker

Lumex — instrumental QC

CE Glycosylation Profiler

LabEx — laboratory QC

Biologic Aggregate Size Quality CheckerCharge Variant CE Quality CheckerProtein Concentration UV Quality CheckerELISA Bioassay Quality CheckerSPR Binding Affinity Quality CheckerEndotoxin Biologic Product Quality CheckerAutomated Sterility Detection Quality CheckerSterility Test Membrane Filtration Quality CheckerBacterial Endotoxins LAL Quality Checker

Medical Devices — equipment and software lifecycle

Supplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology